The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Pharmacyclics Inc

Nasdaq: PCYC
Last

(U.S.) $255.95

Today's change-0.48 -0.19%
Updated March 31 4:00 PM EDT. Delayed by at least 15 minutes.
 

Pharmacyclics Inc

Nasdaq: PCYC
Last

(U.S.) $255.95

Today's change-0.48 -0.19%
Updated March 31 4:00 PM EDT. Delayed by at least 15 minutes.

Pharmacyclics Inc down (U.S.)$0.48

Pharmacyclics Inc closed lower Tuesday, dropping (U.S.)$0.48 or 0.19% to (U.S.)$255.95. Shares have lost 0.70% over the last five days, but sit 1.16% below their 52-week high. This security has outperformed the S&P 500 by 144.94% during the last year.

Key company metrics

  • Open(U.S.) $256.45
  • Previous close(U.S.) $256.43
  • High(U.S.) $256.83
  • Low(U.S.) $255.50
  • Bid / Ask-- / --
  • YTD % change+109.35%
  • Volume824,704
  • Average volume (10-day)987,989
  • Average volume (1-month)2,183,329
  • Average volume (3-month)1,631,844
  • 52-week range(U.S.) $82.51 to (U.S.) $258.95
  • Beta0.67
  • Trailing P/E237.79×
  • P/E 1 year forward514.30×
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $1.08
Updated March 31 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+11.80%

Based on its net profit margin of 11.80%, Pharmacyclics Inc is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.04%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2014Q3/2014Q2/2014Q1/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014
Revenue290207113119
Total other revenue--------
Total revenue290207113119
Gross profit277196104113
Total cost of revenue131296
Total operating expense197159150101
Selling / general / administrative50384535
Research & development48444635
Depreciation / amortization000--
Interest expense (income), net operating--------
Unusual expense (income)86655025
Other operating expenses, total00----
Operating income9348-3718
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax9348-3718
Income after tax6341-3718
Income tax, total30700
Net income6341-3718
Total adjustments to net income--------
Net income before extra. items6341-3718
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items6341-3718
Inc. avail. to common incl. extra. items6341-3718
Diluted net income6341-3718
Dilution adjustment----0--
Diluted weighted average shares79787578
Diluted EPS excluding extraordinary itemsvalue per share0.810.53-0.490.23
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share1.551.24-0.060.44